TENX - Wutah pendapatan taun lumaku Tenax Therapeutics

Tenax Therapeutics (TENX) ensures the reliable delivery of cardiac drugs through diversified express channels, maintaining high margins. The 12-month year-over-year revenue change history on the GURU.Markets chart reflects revenue dynamics, where 0.00 serves as the base parameter value. However, the lack of stable cash flow due to the trial stage and the risk of asset impairment in the event of regulatory failures create significant uncertainties.
Tenax Therapeutics Inc (TENX) - rincian metrik lan laporan keuangan

Tenax Therapeutics (TENX) is developing pulmonary hypertension and heart failure therapies via its TNX-103 drug. This indicator measures the percentage change in revenue over the last 12 months relative to the same period last year. Positive momentum confirms the commercial scalability of the biotech startup and the effectiveness of its market expansion. It is critical for investors to correlate growth rates with clinical trial phases. Analyzing the rolling 12-month sales growth rate year-over-year allows for an assessment of the real speed of asset monetization.